Valuation: Candel Therapeutics, Inc.

Market Cap 706M 618M 570M 524M 992M 67.96B 1.01B 6.8B 2.67B 33.22B 2.65B 2.59B 114B P/E 2026 *
-10.7x
P/E 2027 * -13.6x
Enterprise Value 706M 618M 570M 524M 992M 67.96B 1.01B 6.8B 2.67B 33.22B 2.65B 2.59B 114B EV / Sales 2026 *
-
EV / Sales 2027 * 16.5x
Free-Float
84.33%
Yield 2026 *
-
Yield 2027 * -
07-13 Stifel Nicolaus Initiates Coverage on Candel Therapeutics With Buy Rating, $22 Price Target MT
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-21 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-20 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-20 Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-20 54,895,849 Common Stock of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-15 Candel Therapeutics reports extended clinical benefit over multiple clinical endpoints in patients from phase 3 trial of aglatimagene besadenovec (CAN-2409) RE
05-15 Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (CAN-2409) In Localized Prostate Cancer Under Prolonged Follow-Up At AUA 2026 Annual Meeting CI
05-15 Candel Therapeutics, Inc. - Special Call
05-14 Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI

Last Transcript: Candel Therapeutics, Inc.

1 day-2.33%
1 week-2.43%
Current month-6.41%
1 month+12.62%
3 months+87.18%
6 months+62.29%
Current year+70.62%
1 week 9.19
Extreme 9.19
10.16
1 month 7.93
Extreme 7.93
11.36
Current year 4.44
Extreme 4.44
11.36
1 year 4.35
Extreme 4.35
11.36
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.78
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 2020-08-31
Director of Finance/CFO 41 2024-01-11
Chief Tech/Sci/R&D Officer 57 2022-09-11
Director TitleAgeSince
Director/Board Member 80 2017-08-31
Director/Board Member 66 2020-08-31
Chairman 70 2021-07-14
Date Insider Type Main position Quantity % Market Cap.
07-05Free

Executive/Senior Manager

285,000 0.3890%
06-29Free

Chairman

2,199 0.0030%
06-29Free

Director

381 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-2.43%+54.24%+731.03% 723M
-0.17%+1.47%+3.16%+6.80% 50.35B
-0.29%-2.81%+387.81%+591.82% 39.32B
-0.49%+1.48%+31.16%-6.46% 34.69B
+1.53%+3.11%+15.41%+58.54% 34.08B
+1.68%-0.62%+3.30%+27.34% 26.63B
+1.13%-3.11% - - 16.49B
-1.29%-0.52%+69.24%+117.60% 15.31B
+0.43%+3.34%+14.96%+17.46% 13.8B
+2.45%+3.99%+18.20%-30.12% 12.87B
Average +0.26%+0.59%+66.39%+168.22% 24.43B
Weighted average by Cap. +0.39%+0.78%+81.85%+124.23%

Financials

2026 *2027 *
Net sales - 42.84M 37.45M 34.55M 31.76M 60.17M 4.12B 61.2M 412M 162M 2.01B 161M 157M 6.94B
Net income -61.55M -53.81M -49.64M -45.63M -86.46M -5.92B -87.94M -593M -233M -2.89B -231M -226M -9.98B -54.13M -47.32M -43.65M -40.13M -76.03M -5.21B -77.33M -521M -204M -2.55B -203M -199M -8.77B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
26-07-15 US$9.640 -2.33% 1,157,728
26-07-14 US$9.870 +2.39% 1,425,091
26-07-13 US$9.640 +1.58% 1,627,557
26-07-10 US$9.490 -4.04% 1,190,965
26-07-09 US$9.890 +0.10% 1,101,829
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.640USD
Average target price
20.50USD
Spread / Average Target
+112.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock